June 13 Company Quick Takes: ISS rebuffs Takeda’s Weber; plus Sage, Blueprint, Tetraphase, Celgene and more

ISS weighs in on Weber
Institutional Shareholder Services recommended Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) shareholders oppose President and CEO Christophe Weber at the June 27 shareholder meeting because “top management is responsible for the company’s unfavorable” financial performance. In its report, the influential proxy advisory firm

Read the full 466 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE